bay-85-8501

Description: BAY 85-8501 is a novel, highly potent and selective inhibitor of Human Neutrophil Elastase (HNE) with an IC50 of 65 pM. BAY 85-8501 exhibited high in vivo efficacy in various preclinical animal models and is currently being studied in clinical studies for the treatment of pulmonary diseases. Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors should reestablish the protease-anti-protease balance. By means of medicinal chemistry a novel dihydropyrimidinone lead-structure class was identified. Further chemical optimization yielded orally active compounds with favorable pharmacokinetics such as the chemical probe BAY-678. While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned methyl sulfone substituent. An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE. BAY 85-8501 ((4S)-4-4-cyano-2-(methylsulfonyl)phenyl-3, 6-dimethyl-2-oxo-1-3-(trifluoromethyl)phenyl-1, 2, 3, 4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI. BAY 85-8501 is currently being tested in clinical studies for the treatment of pulmonary diseases.

References: ChemMedChem. 2015 Jul; 10(7):1163-73.